Thioredoxin Interacting Protein Is a Potential Regulator of Glucose and Energy Homeostasis in Endogenous Cushing's Syndrome

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Lekva, Tove ^a,b,c   Bollerslev, Jens ^a,c   Sahraoui, Afaf ^a   Scholz, Hanne ^a   Bøyum, Hege ^a   Evang, Johan Arild ^a,b   Godang, Kristin ^a   Aukrust, Pål ^a,b,c   Ueland, Thor ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INTERLEUKIN 8; MESSENGER RNA; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; CARRIER PROTEIN; PRIMER DNA; TXNIP PROTEIN, HUMAN;

ADULT; ARTICLE; BONE BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; DOWN REGULATION; ENERGY BALANCE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC REGULATION; OSTEOBLAST; PANCREAS ISLET CELL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ANALYSIS OF VARIANCE; BONE; ENERGY METABOLISM; GENE SILENCING; GENETICS; HOMEOSTASIS; METABOLISM; MICROARRAY ANALYSIS; PANCREAS ISLET; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; BLOTTING, WESTERN; BONE AND BONES; CARRIER PROTEINS; CUSHING SYNDROME; DNA PRIMERS; ENERGY METABOLISM; GENE SILENCING; GLUCOSE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-8; ISLETS OF LANGERHANS; MICROARRAY ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84877857626     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064247     Document Type: Article

References (40)

1. Resmini E, Minuto F, Colao A, Ferone D, (2009) Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 46: 85-95.
2. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP, (2009) Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 94: 2692-2701.
3. Chanson P, Salenave S, (2010) Metabolic syndrome in Cushing's syndrome. Neuroendocrinology 92 (Suppl 1) (): 96-101.
4. van ZB, Reuwer AQ, Buller HR, Kastelein JJ, Gerdes VE, et al. (2009) Hormones and cardiovascular disease: a shift in paradigm with clinical consequences? Semin Thromb Hemost 35: 478-487.
5. Fulzele K, Clemens TL, (2012) Novel functions for insulin in bone. Bone 50: 452-456.
6. Karsenty G, Ferron M, (2012) The contribution of bone to whole-organism physiology. Nature 481: 314-320.
7. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456-469.
8. Ferron M, Wei J, Yoshizawa T, Del FA, DePinho RA, et al. (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142: 296-308.
9. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, et al. (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142: 309-319.
10. Godang K, Ueland T, Bollerslev J, (1999) Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome. Eur J Endocrinol 141: 126-131.
11. Barahona MJ, Sucunza N, Resmini E, Fernandez-Real JM, Ricart W, et al. (2009) Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. J Bone Miner Res 24: 1841-1846.
12. Sereg M, Toke J, Patocs A, Varga I, Igaz P, et al. (2011) Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing's syndrome. Steroids 76: 38-42.
13. Hwang YC, Jeong IK, Ahn KJ, Chung HY, (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25: 768-772.
14. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, et al. (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24: 785-791.
15. Kakisaka Y, Nakashima T, Sumida Y, Yoh T, Nakamura H, et al. (2002) Elevation of serum thioredoxin levels in patients with type 2 diabetes. Horm Metab Res 34: 160-164.
16. Miyamoto S, Kawano H, Hokamaki J, Soejima H, Kojima S, et al. (2005) Increased plasma levels of thioredoxin in patients with glucose intolerance. Intern Med 44: 1127-1132.
17. Okuda M, Inoue N, Azumi H, Seno T, Sumi Y, et al. (2001) Expression of glutaredoxin in human coronary arteries: its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21: 1483-1487.
18. Kaimul AM, Nakamura H, Masutani H, Yodoi J, (2007) Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med 43: 861-868.
19. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, et al. (1999) Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650.
20. Minn AH, Hafele C, Shalev A, (2005) Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146: 2397-2405.
21. Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, et al. (2007) TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 4: e158.
22. Hui TY, Sheth SS, Diffley JM, Potter DW, Lusis AJ, et al. (2004) Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem 279: 24387-24393.
23. Oka S, Liu W, Masutani H, Hirata H, Shinkai Y, et al. (2006) Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. FASEB J 20: 121-123.
24. Lekva T, Bollerslev J, Kristo C, Olstad OK, Ueland T, et al. (2010) The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing's syndrome and may play a role in glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 95: 246-255.
25. Lekva T, Ueland T, Boyum H, Evang JA, Godang K, et al. (2012) TXNIP is highly regulated in bone biopsies from patients with Endogenous Cushing's Syndrome and related to bone turnover. Eur J Endocrinol 166: 1039-1048.
26. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, et al. (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410.
27. Levy JC, Matthews DR, Hermans MP, (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21: 2191-2192.
28. Goto M, Johansson U, Eich TM, Lundgrem T, Engkvist M, et al. (2005) Key factors for human islet isolation and clinical transplantation. Transplant Proc 37: 1315-1316.
29. Chen J, Fontes G, Saxena G, Poitout V, Shalev A, (2010) Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes 59: 440-447.
30. Rani S, Mehta JP, Barron N, Doolan P, Jeppesen PB, et al. (2010) Decreasing Txnip mRNA and protein levels in pancreatic MIN6 cells reduces reactive oxygen species and restores glucose regulated insulin secretion. Cell Physiol Biochem 25: 667-674.
31. Yamamoto M, Yamato E, Toyoda S, Tashiro F, Ikegami H, et al. (2008) Transgenic expression of antioxidant protein thioredoxin in pancreatic beta cells prevents progression of type 2 diabetes mellitus. Antioxid Redox Signal 10: 43-49.
32. Motyl KJ, McCabe LR, Schwartz AV, (2010) Bone and Glucose Metabolism: A Two-Way Street. Arch Biochem Biophys 503: 2-10.
33. Koenen TB, Stienstra R, van Tits LJ, de GJ, Stalenhoef AF, et al. (2011) Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue. Diabetes 60: 517-524.
34. Dostert A, Heinzel T, (2004) Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 10: 2807-2816.
35. Mancini T, Doga M, Mazziotti G, Giustina A, (2004) Cushing's syndrome and bone. Pituitary 7: 249-252.
36. Munir A, Newell-Price J, (2010) Management of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 92 (Suppl 1) (): 82-85.
37. Schroder K, Zhou R, Tschopp J, (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science 327: 296-300.
38. Brennan-Speranza TC, Henneicke H, Gasparini SJ, Blankenstein KI, Heinevetter U, et al. (2012) Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest 122: 4172-4189.
39. Kristo C, Godang K, Ueland T, Lien E, Aukrust P, et al. (2002) Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome. Eur J Endocrinol 146: 389-395.
40. Igoillo-Esteve M, Marselli L, Cunha DA, Ladriere L, Ortis F, et al. (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 53: 1395-1405.